低密度脂蛋白胆固醇对微血管与大血管疾病的影响:一项孟德尔随机化研究
本研究采用单样本和两样本孟德尔随机化及随机试验荟萃分析,探讨高LDL-C是否因果关联视网膜病变、神经病变、慢性肾脏病和外周动脉疾病。结果显示高LDL-C与视网膜病变和神经病变无因果关联,但与慢性肾脏病和外周动脉疾病存在观察性和遗传学关联,提示LDL-C因果参与后两者发病。
要点
- 高LDL-C与视网膜病变、神经病变无因果关联
- 高LDL-C观察性和遗传学上均与慢性肾脏病和外周动脉疾病风险升高相关
- 他汀治疗降低LDL-C可改善eGFR,支持LDL-C在慢性肾脏病中的因果作用
核心结论
- 高LDL-C与视网膜病变和神经病变无因果关联,但与慢性肾脏病和外周动脉疾病存在观察性和遗传学关联,提示LDL-C因果参与这些疾病的发病。
研究设计与样本
- 研究对116,419名丹麦个体进行单样本孟德尔随机化。
- 研究使用全球脂质遗传学联盟(GLGC,n=94,595)和英国生物银行(n=408,455)的汇总数据进行两样本孟德尔随机化。
- 研究对随机他汀试验(n=64,134)进行荟萃分析。
主要发现
- 观察性分析中,高LDL-C与视网膜病变或神经病变高风险无关。
- 观察性分析中,LDL-C高于第95百分位 versus 低于第50百分位,慢性肾脏病风险比1.05(95%CI:0.97-1.13),外周动脉疾病风险比1.41(95%CI:1.23-1.62),趋势p<0.001。
- 哥本哈根研究遗传因果分析中,LDL-C每升高1 mmol/l,视网膜病变风险比1.06(95%CI:0.24-4.58),神经病变1.05(95%CI:0.64-1.72),慢性肾脏病3.83(95%CI:2.00-7.34),外周动脉疾病2.09(95%CI:1.30-2.38)。
- GLGC和英国生物银行汇总数据关于视网膜病变、神经病变和外周动脉疾病的结果相似。
- LDL-C每降低1 mmol/l,观察性分析中eGFR升高1.95 ml/min/1.73 m2(95%CI:1.88-2.02),遗传学分析中升高5.92 ml/min/1.73 m2(95%CI:4.97-6.86),他汀治疗中升高2.69 ml/min/1.73 m2(95%CI:1.48-3.94)。
临床怎么用
- 对于高LDL-C患者,应关注慢性肾脏病和外周动脉疾病的风险评估与管理。
- 他汀治疗降低LDL-C可能有助于改善肾功能(eGFR),支持在慢性肾脏病防治中管理LDL-C。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is causally associated with a high risk of coronary artery disease. Whether this also holds for a spectrum of peripheral vascular diseases is unknown. OBJECTIVES: The purpose of this study was to determine whether high LDL-C causally relates to risk of retinopathy, neuropathy, chronic kidney disease (CKD), and peripheral arterial disease (PAD) in the general population. METHODS: One-sample Mendelian randomization (MR) of 116,419 Danish individuals, 2-sample MR on summary-level data from the Global Lipid Genetics Consortium (GLGC) (n = 94,595) and the UK Biobank (n = 408,455), and meta-analysis of randomized statin trials (n = 64,134) were performed. RESULTS: Observationally, high LDL-C did not associate with high risk of retinopathy or neuropathy. There were stepwise increases in risk of CKD and PAD with higher LDL-C (both p for trend <0.001), with hazard ratios of 1.05 (95% confidence interval [CI]: 0.97 to 1.13) for CKD, and 1.41 (95% CI: 1.23 to 1.62) for PAD in individuals with LDL-C above the 95th percentile versus below the 50th percentile. In genetic, causal analyses in the Copenhagen studies, the risk ratio of disease for a 1 mmol/l higher LDL-C was 1.06 (95% CI: 0.24 to 4.58) for retinopathy, 1.05 (95% CI: 0.64 to 1.72) for neuropathy, 3.83 (95% CI: 2.00 to 7.34) for CKD, and 2.09 (95% CI: 1.30 to 2.38) for PAD. Summary-level data from the GLGC and the UK Biobank for retinopathy, neuropathy, and PAD gave similar results. For CKD, a 1-mmol/l lower LDL-C conferred a higher eGFR of 1.95 ml/min/1.73 m2 (95% CI: 1.88 to 2.02 ml/min/1.73 m2) observationally, 5.92 ml/min/1.73 m2 (95% CI: 4.97 to 6.86 ml/min/1.73 m2) genetically, and 2.69 ml/min/1.73 m2 (95% CI: 1.48 to 3.94 ml/min/1.73 m2) through statin therapy. CONCLUSIONS: High LDL-C was not causally associated with risk of retinopathy and neuropathy; however, high LDL-C was observationally and genetically associated with high risks of PAD and CKD, suggesting that LDL-C is causally involved in the pathogenesis of these diseases.
引用
- Emanuelsson F, Nordestgaard BG, Tybjærg-Hansen A, et al. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2019. PMID: 31514949. doi:10.1016/j.jacc.2019.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。